Buddy Day, a seasoned sales executive, brings more than 20 years of experience to CoreLink LLC as one of the company’s four new regional Vice Presidents of Sales. Day also brings a wide range of deep relationships with surgeons, distributors, and hospitals throughout the Midwest. CoreLink, a spine company based in St. Louis, Missouri, indicates that it is bringing new talent on board due to an aggressive investments in new product development and a commitment to their surgeon and distributor partners.
Buddy Day: New Regional Vice President of Sales at CoreLink
1 min read Premium comments
Secondary#corelink#buddyday
Day commented, “I believe I understand the spine industry from many perspectives. CoreLink is uniquely positioned with a full portfolio of products and new innovative products are consistently being developed, such as the Mimetic Metal family of 3D printed interbodies. Their commitment to innovation is a perfect fit for me.”
“Buddy has a unique combination of experience as a successful independent distributor and a track record of sustained revenue growth as a medical device sales executive. We are especially excited about Buddy’s experience in novel technology introductions to the spine market. This melds perfectly with our robust, differentiated platform of additively manufactured Mimetic Metal products and innovative spine systems,” Derek Kuyper, vice president of CoreLink.
Buddy Day told OTW, “I look forward to introducing CoreLink to new surgeon, distributor, and hospital customers. I believe we will experience tremendous growth in the coming year.”
This company takes a cue from the adage, “If you want it done right, do it yourself.” CoreLink designs and manufactures more than 99% of its instruments and implants. They are anticipating several product launches in the coming months.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.